Daily Market Reports | Nov 27 2025
This story features ACCENT GROUP LIMITED, and other companies.
For more info SHARE ANALYSIS: AX1
The company is included in ASX300 and ALL-ORDS
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely “regularly” depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena’s team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
AX1 BEN GTK IAG IPX KGN LGI LYC MSB PYC QUB REH SUN VR1 WR1
AX1 ACCENT GROUP LIMITED
Apparel & Footwear – Overnight Price: $1.03
Petra Capital rates ((AX1)) as Downgrade to Hold from Buy (3) –
Accent Group delivered a weak AGM trading update, assesses Petra Capital, with financial year-to-date like-for-like sales slipping to -0.4% after an early improvement. The broker lowers its target to $1.08 from $1.65 and downgrades to Hold from Buy.
The gross margin contracted -160bps as the group increased promotional activity to manage inventory, driven largely by underperformance in lifestyle footwear, explains the analyst. It’s noted sports categories continued to trade well.
Earnings (EBIT) guidance was materially downgraded to $55m-$60m from around $80m for 1H26 and $85m-$95m from circa $118m for FY26.
Petra Capital believes category-specific issues, including a lack of new lifestyle product amid intense competition, are the primary drag rather than macro factors alone.
This report was published on November 24, 2025.
Target price is $1.08 Current Price is $1.03 Difference: $0.045
If AX1 meets the Petra Capital target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $1.07, suggesting upside of 3.0%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Petra Capital forecasts a full year FY26 dividend of 5.30 cents and EPS of 7.50 cents.
At the last closing share price the estimated dividend yield is 5.12%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.80.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 7.0, implying annual growth of -30.8%.
Current consensus DPS estimate is 4.8, implying a prospective dividend yield of 4.6%.
Current consensus EPS estimate suggests the PER is 14.8.
Forecast for FY27:
Petra Capital forecasts a full year FY27 dividend of 5.80 cents and EPS of 8.20 cents.
At the last closing share price the estimated dividend yield is 5.60%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.62.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 8.7, implying annual growth of 24.3%.
Current consensus DPS estimate is 5.9, implying a prospective dividend yield of 5.7%.
Current consensus EPS estimate suggests the PER is 11.9.
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
BEN BENDIGO & ADELAIDE BANK LIMITED
Banks – Overnight Price: $10.21
Jarden rates ((BEN)) as Neutral (3) –
Jarden obseves Deloitte found widespread deficiencies across the Bendigo & Adelaide Bank branch network after an investigation into suspicious activity from August 2019 to August 2025.
The broker highlights weaknesses in the bank’s anti-money laundering and counter-terrorism financing risk assessment, customer due diligence, oversight, transaction monitoring and customer risk rating.
Jarden sees parallels with prior cases in the bank sector that led to heavy fines, capital add-ons and enforceable undertakings. It is thought Bendigo & Adelaide Bank faces heightened regulatory and valuation risk.
Target price reduced to $11.00 from $12.00. Neutral rating retained.
This report was published on November 25, 2025.
Target price is $11.00 Current Price is $10.21 Difference: $0.79
If BEN meets the Jarden target it will return approximately 8% (excluding dividends, fees and charges).
Current consensus price target is $11.10, suggesting upside of 8.7%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 63.00 cents and EPS of 83.00 cents.
At the last closing share price the estimated dividend yield is 6.17%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.30.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 85.6, implying annual growth of N/A.
Current consensus DPS estimate is 63.0, implying a prospective dividend yield of 6.2%.
Current consensus EPS estimate suggests the PER is 11.9.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 66.00 cents and EPS of 87.40 cents.
At the last closing share price the estimated dividend yield is 6.46%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 11.68.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 88.1, implying annual growth of 2.9%.
Current consensus DPS estimate is 63.0, implying a prospective dividend yield of 6.2%.
Current consensus EPS estimate suggests the PER is 11.6.
Market Sentiment: -0.6
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
GTK GENTRACK GROUP LIMITED
Software & Services – Overnight Price: $9.24
Jarden rates ((GTK)) as Underweight (4) –
Jarden observes Gentrack’s revenue growth has slowed to 8% y/y in FY25 and FY26 guidance points to a similar pace as the company works through a pipeline transition and early g2.0 deployments.
Positively, Genesis is now live on part of its B2C base and ACEN Energy is due to go live on a small B2B book in 1Q26.
Management outlined a near term pipeline of 10 prospects representing 30m meter points and around NZ$136m of estimated recurring revenue where the group is preferred on three and short listed on another three, with execution over the next 12 months seen as critical to returning to 15%-plus growth in FY27.
On softer guidance and delayed conversion, the broker cuts FY26 to FY28 revenue forecasts by about -8% and near term (earnings) EBITDA by about -20%, lowering the target price to NZ$8.85 from NZ$8.95.
Jarden retains an Underweight rating.
This report was published on November 25, 2025.
Current Price is $9.24. Target price not assessed.
Current consensus price target is $10.00, suggesting upside of 8.2%(ex-dividends)
The company’s fiscal year ends in September.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 17.75 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 52.06.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 16.7, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 55.3.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of 26.63 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 34.70.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 23.7, implying annual growth of 41.9%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 39.0.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
IAG INSURANCE AUSTRALIA GROUP LIMITED
Insurance – Overnight Price: $7.68
Jarden rates ((IAG)) as Upgrade to Overweight from Neutral (2) –
A change of analyst at Jarden results in a reordering of domestic general insurance preferences, upgrading Insurance Australia Group to Overweight from Neutral and downgrading Suncorp ((SUN)) to Neutral from Overweight.
The broker mentions better risk reward in Insurance Australia Group as organic tailwinds fade.
The new analyst argues the premium rate momentum is contracting across commercial, personal lines and NZ, making Suncorp’s push for organic commercial growth harder despite its favourable consumer mix.
While Suncorp is seen as better positioned for organic consumer driven growth, the broker expects both majors to face market share pressure and trims gross written premium forecasts by about -1%.
Insurance Australia Group is viewed as having a catalyst rich outlook, including potential RACWA approval, FY27 cost out upside, commercial capital optimisation, and quota share reinsurance commission benefits.
EPS forecasts are downgraded around -1% for each insurer. Insurance Australia Group target is lowered to $8.20 from $8.30.
This report was published on November 24, 2025.
Target price is $8.20 Current Price is $7.68 Difference: $0.52
If IAG meets the Jarden target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $9.11, suggesting upside of 18.7%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 33.00 cents and EPS of 45.10 cents.
At the last closing share price the estimated dividend yield is 4.30%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 17.03.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 44.2, implying annual growth of -23.1%.
Current consensus DPS estimate is 30.7, implying a prospective dividend yield of 4.0%.
Current consensus EPS estimate suggests the PER is 17.4.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 33.00 cents and EPS of 45.10 cents.
At the last closing share price the estimated dividend yield is 4.30%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 17.03.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 48.8, implying annual growth of 10.4%.
Current consensus DPS estimate is 34.3, implying a prospective dividend yield of 4.5%.
Current consensus EPS estimate suggests the PER is 15.7.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
IPX IPERIONX LIMITED
Industrial Metals – Overnight Price: $4.85
Petra Capital rates ((IPX)) as Buy (1) –
Petra Capital reiterates a Buy rating and $9.90 target for IperionX after visiting the titanium metal plant and R&D campus in Virginia, US.
The plant is ramping up with increasing repeatability, supported by US government funding and a growing customer list.
Commentary suggests R&D work indicates the path to a much bigger and lower-cost expansion could be possible.
Catalysts include more binding customer contracts and a progressive increase in metals revenue in the first half along with data on incremental production processes.
This report was published on November 24, 2025.
Target price is $9.90 Current Price is $4.85 Difference: $5.05
If IPX meets the Petra Capital target it will return approximately 104% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 3.10 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 156.45.
Forecast for FY27:
Petra Capital forecasts a full year FY27 EPS of 15.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 31.70.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
KGN KOGAN.COM LIMITED
Retailing – Overnight Price: $3.14
Canaccord Genuity rates ((KGN)) as Buy (1) –
Kogan’s FY26 to date trading update at the AGM was broadly in line with Canaccord Genuity’s expectations , with strong Kogan.com performance offset by a weaker MightyApe result.
Group gross sales rose sharply, but revenue and profit growth were modest and adjusted earnings (EBITDA) fell y/y, which the broker attributes to the NZ turnaround. Kogan.com gained from funds reinvested into marketing and subscriptions.
MightyApe is still dragging earnings due to inventory right sizing and clearance activity, though management points to early signs of improvement and expects profitability to return in 2H26.
FY26 margin guidance is maintained. The broker reiterates a Buy rating and $7.50 target price, making only slight changes to earnings estimates.
This report was published on November 24, 2025.
Target price is $7.50 Current Price is $3.14 Difference: $4.36
If KGN meets the Canaccord Genuity target it will return approximately 139% (excluding dividends, fees and charges).
Current consensus price target is $4.40, suggesting upside of 40.1%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 14.60 cents and EPS of 22.50 cents.
At the last closing share price the estimated dividend yield is 4.65%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.96.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 17.7, implying annual growth of N/A.
Current consensus DPS estimate is 11.3, implying a prospective dividend yield of 3.6%.
Current consensus EPS estimate suggests the PER is 17.7.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 17.80 cents and EPS of 27.40 cents.
At the last closing share price the estimated dividend yield is 5.67%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 11.46.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 19.7, implying annual growth of 11.3%.
Current consensus DPS estimate is 15.3, implying a prospective dividend yield of 4.9%.
Current consensus EPS estimate suggests the PER is 15.9.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
LGI LGI LIMITED
Overnight Price: $4.20
Canaccord Genuity rates ((LGI)) as Buy (1) –
Canaccord Genuity highlights LGI’s recent equity raise, accelerated project timetable, and a larger growth runway as key positives, keeping a Buy rating and lifting the target price to $4.80 from $4.30.
The company raised $56m at $3.85 per share to strengthen the balance sheet and pull forward the 11MW Nowra project, now expected to commission in FY27 rather than later years.
Funding also supports a lift in medium term installed capacity to more than 80MW, up from the prior 56MW plan, with a further 25MW-plus pipeline including extensions and new battery backed projects.
Increasing power price volatility in Queensland and NSW is viewed as improving the economics for batteries, which LGI is expanding alongside generation assets. FY26 guidance is unchanged for 25 to 30% y/y earnings (EBITDA) growth.
This report was published on November 25, 2025.
Target price is $4.80 Current Price is $4.20 Difference: $0.6
If LGI meets the Canaccord Genuity target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $4.78, suggesting upside of 13.8%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 2.50 cents and EPS of 9.90 cents.
At the last closing share price the estimated dividend yield is 0.60%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 42.42.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 10.1, implying annual growth of 38.5%.
Current consensus DPS estimate is 2.9, implying a prospective dividend yield of 0.7%.
Current consensus EPS estimate suggests the PER is 41.6.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 2.50 cents and EPS of 11.50 cents.
At the last closing share price the estimated dividend yield is 0.60%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 36.52.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 12.5, implying annual growth of 23.8%.
Current consensus DPS estimate is 3.8, implying a prospective dividend yield of 0.9%.
Current consensus EPS estimate suggests the PER is 33.6.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
LYC LYNAS RARE EARTHS LIMITED
Rare Earth Minerals – Overnight Price: $15.00
Canaccord Genuity rates ((LYC)) as Buy (1) –
Lynas Rare Earths announced output from its MREC plant in Kalgoorlie will be hit in the December quarter by ongoing power disruptions.
The company expects a one-month production shortfall, though it claims this can be recovered later in FY26, Canaccord Genuity highlights. The broker cut December quarter NdPr production to 1.8kt from 2.7kt, implying -20% lower revenue and -35% lower EBITDA, partly cushioned by inventory.
All else equal, the broker reduces forecast FY26 EBITDA by -8% to $524m, with added downside risk given uncertain power reliability and planned capacity ramp increasing demand.
Buy. Target unchanged at $15.55.
This report was published on November 25, 2025.
Target price is $15.55 Current Price is $15.00 Difference: $0.55
If LYC meets the Canaccord Genuity target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $14.04, suggesting downside of -6.4%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 31.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 48.39.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 33.9, implying annual growth of 3888.2%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 44.2.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 74.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 20.27.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 58.2, implying annual growth of 71.7%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 25.8.
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
MSB MESOBLAST LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $2.72
Canaccord Genuity rates ((MSB)) as Buy (1) –
Mesoblast’s AGM update on Ryoncil was very strong, Canaccord Genuity remarks, with launch pace ahead of expectations. The company expects 2Q gross revenue of over US$30m, up 38% q/q, while most high-volume centres are now onboarded.
Pipeline commentary is described as upbeat, with R&D progressing across several high-value indications. Inflammatory colitis is moving toward an IND filing in 1Q2026.
The broker highlights the next 12 months look catalyst-rich, with Ryoncil helping fund broader clinical development and increasing chances of clinical/commercial partnerships.
Buy. Target price $3.11.
This report was published on November 25, 2025.
Target price is $3.11 Current Price is $2.72 Difference: $0.39
If MSB meets the Canaccord Genuity target it will return approximately 14% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
PYC PYC THERAPEUTICS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $1.49
Canaccord Genuity rates ((PYC)) as Buy (1) –
PYC Therapeutics has reported encouraging progress in two of its drug programs, one for a genetic kidney disease (ADPKD) and one for an inherited eye disease (RP11), Canaccord Genuity notes.
In the eye study, early phase results for VP-001 show patients’ vision measures have improved and those gains have held up over longer follow-up, which is a good sign because the disease normally worsens with time.
In the kidney study, the new drug PYC-003 has so far looked safe, letting the company move to a higher dose in the next patient group, with the first indications of whether it helps patients expected in early to mid 2026 and more complete repeat dose results by late 2026.
The kidney program is viewed as the biggest driver of the biotech’s valuation. Buy rating and a $2.85 target price retained.
This report was published on November 24, 2025.
Target price is $2.85 Current Price is $1.49 Difference: $1.365
If PYC meets the Canaccord Genuity target it will return approximately 92% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 13.60 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 10.92.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 18.80 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 7.90.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
QUB QUBE HOLDINGS LIMITED
Transportation & Logistics – Overnight Price: $4.87
Jarden rates ((QUB)) as Neutral (3) –
Jarden notes Qube has received a conditional, non binding $5.20 per share all cash indicative offer from Macquarie Asset Management ((MQG)), and the board has unanimously recommended it, granting exclusivity for due diligence through 1 February 2026.
The broker sees regulatory risk as relatively modest, with ACCC and FIRB approvals required but only limited asset overlap flagged, mainly around Port of Newcastle and the Newcastle Agri Terminal.
On valuation, the analyst views the bid as firming value for Patrick and implying a reasonable stub valuation for the remaining operating and property assets.
Jarden retains its earnings forecasts with the main point of interest is the ACCC process and any need for selective divestments to secure approval. Target raised to $5 from $4.25 with no change in Neutral rating.
This report was published on November 24, 2025.
Target price is $5.00 Current Price is $4.87 Difference: $0.13
If QUB meets the Jarden target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $5.10, suggesting upside of 4.7%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 9.50 cents and EPS of 16.90 cents.
At the last closing share price the estimated dividend yield is 1.95%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 28.82.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 15.9, implying annual growth of 148.4%.
Current consensus DPS estimate is 10.4, implying a prospective dividend yield of 2.1%.
Current consensus EPS estimate suggests the PER is 30.6.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 11.40 cents and EPS of 20.40 cents.
At the last closing share price the estimated dividend yield is 2.34%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 23.87.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 17.7, implying annual growth of 11.3%.
Current consensus DPS estimate is 11.3, implying a prospective dividend yield of 2.3%.
Current consensus EPS estimate suggests the PER is 27.5.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
REH REECE LIMITED
Furniture & Renovation – Overnight Price: $12.24
Jarden rates ((REH)) as Neutral (3) –
Reece’s 1Q26 trading update shows early improvement in underlying trends, even as end markets stay soft and margins remain pressured due to ongoing investment, Jarden observes.
Revenue was well ahead of consensus, helped by store network expansion and better than expected like for like sales in A&NZ, while US like for like sales were still slightly negative but held up reasonably in a tough construction backdrop.
Management’s AGM comments on the US business were viewed as incrementally more positive, particularly around Waterworks and leadership, suggesting groundwork for recovery when conditions normalise.
The analyst lifts EPS forecasts modestly for FY26 to FY28, reflecting higher revenue expectations offset by lower margin assumptions and slightly higher interest costs.
Neutral rating and an unchanged $12.30 target price.
This report was published on November 24, 2025.
Target price is $12.30 Current Price is $12.24 Difference: $0.06
If REH meets the Jarden target it will return approximately 0% (excluding dividends, fees and charges).
Current consensus price target is $12.11, suggesting downside of -1.1%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 17.10 cents and EPS of 44.50 cents.
At the last closing share price the estimated dividend yield is 1.40%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 27.51.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 43.9, implying annual growth of -10.8%.
Current consensus DPS estimate is 16.8, implying a prospective dividend yield of 1.4%.
Current consensus EPS estimate suggests the PER is 27.9.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 20.20 cents and EPS of 51.50 cents.
At the last closing share price the estimated dividend yield is 1.65%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 23.77.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 48.0, implying annual growth of 9.3%.
Current consensus DPS estimate is 21.4, implying a prospective dividend yield of 1.7%.
Current consensus EPS estimate suggests the PER is 25.5.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
SUN SUNCORP GROUP LIMITED
Insurance – Overnight Price: $18.57
Jarden rates ((SUN)) as Downgrade to Neutral from Overweight (3) –
A change of analyst at Jarden results in a reordering of domestic general insurance preference, upgrading Insurance Australia Group ((IAG)) to Overweight from Neutral and downgrading Suncorp to Neutral from Overweight.
The motivation given is a better risk reward in Insurance Australia Group as organic tailwinds fade.
The new analyst argues the premium rate momentum is contracting across commercial, personal lines and NZ, making Suncorp’s push for organic commercial growth harder despite its favourable consumer mix.
While Suncorp is seen as better positioned for organic consumer driven growth, the broker expects both majors to face market share pressure and trims gross written premium forecasts by about -1%.
Insurance Australia Group is viewed as having a catalyst rich outlook, including potential RACWA approval, FY27 cost out upside, commercial capital optimisation, and quota share reinsurance commission benefits.
EPS forecasts are downgraded around -1% for each insurer. Suncorp’s target is lowered to $19.50 from $21.60.
This report was published on November 24, 2025.
Target price is $19.50 Current Price is $18.57 Difference: $0.93
If SUN meets the Jarden target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $22.63, suggesting upside of 21.9%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 89.00 cents and EPS of 123.30 cents.
At the last closing share price the estimated dividend yield is 4.79%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.06.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 118.6, implying annual growth of -15.4%.
Current consensus DPS estimate is 87.7, implying a prospective dividend yield of 4.7%.
Current consensus EPS estimate suggests the PER is 15.7.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 86.00 cents and EPS of 120.50 cents.
At the last closing share price the estimated dividend yield is 4.63%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.41.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 125.3, implying annual growth of 5.6%.
Current consensus DPS estimate is 92.1, implying a prospective dividend yield of 5.0%.
Current consensus EPS estimate suggests the PER is 14.8.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
VR1 VECTION TECHNOLOGIES LIMITED
Overnight Price: $0.03
Petra Capital rates ((VR1)) as Initiation of coverage with Buy (1) –
Petra Capital initiates coverage of Vection Technologies with a Buy rating and 7c target. The company is founder-led and focused on spatial computing and AI solutions. Clients span a broad range of sectors and include many blue-chip organisations.
The company has an integrated proprietary XR and AI platform enabling a single point of access and easy cross-sell, the broker notes.
Petra Capital believes the stock is in the early stages of a re-rating, the business moving into positive EBITDA this year and free cash flow by FY27 as scale benefits emerge.
This report was published on November 25, 2025.
Target price is $0.07 Current Price is $0.03 Difference: $0.036
If VR1 meets the Petra Capital target it will return approximately 106% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 0.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 11.33.
Forecast for FY27:
Petra Capital forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 0.10 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 34.00.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
WR1 WINSOME RESOURCES LIMITED
New Battery Elements – Overnight Price: $0.29
Canaccord Genuity rates ((WR1)) as Speculative Buy (1) –
Winsome Resources’ 2025 Adina drill program returned strong assays, confirming robust near-surface mineralisation and improving understanding of the Footwall Zone, Canaccord Genuity observes.
29 holes (5,302m) delivered multiple shallow, thick, high-grade Main Zone hits plus solid Footwall intercepts at depth, with extensional drilling showing the deposit is still open north and east.
The results will feed into an upcoming MRE for the Feasibility Study. Current MRE is 78Mt at 1.15% lithium oxide. Speculative Buy with unchanged target of 75c.
This report was published on November 25, 2025.
Target price is $0.75 Current Price is $0.29 Difference: $0.455
If WR1 meets the Canaccord Genuity target it will return approximately 154% (excluding dividends, fees and charges).
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don’t have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.
Click to view our Glossary of Financial Terms
CHARTS
For more info SHARE ANALYSIS: AX1 - ACCENT GROUP LIMITED
For more info SHARE ANALYSIS: BEN - BENDIGO & ADELAIDE BANK LIMITED
For more info SHARE ANALYSIS: GTK - GENTRACK GROUP LIMITED
For more info SHARE ANALYSIS: IAG - INSURANCE AUSTRALIA GROUP LIMITED
For more info SHARE ANALYSIS: IPX - IPERIONX LIMITED
For more info SHARE ANALYSIS: KGN - KOGAN.COM LIMITED
For more info SHARE ANALYSIS: LGI - LGI LIMITED
For more info SHARE ANALYSIS: LYC - LYNAS RARE EARTHS LIMITED
For more info SHARE ANALYSIS: MQG - MACQUARIE GROUP LIMITED
For more info SHARE ANALYSIS: MSB - MESOBLAST LIMITED
For more info SHARE ANALYSIS: PYC - PYC THERAPEUTICS LIMITED
For more info SHARE ANALYSIS: QUB - QUBE HOLDINGS LIMITED
For more info SHARE ANALYSIS: REH - REECE LIMITED
For more info SHARE ANALYSIS: SUN - SUNCORP GROUP LIMITED
For more info SHARE ANALYSIS: VR1 - VECTION TECHNOLOGIES LIMITED
For more info SHARE ANALYSIS: WR1 - WINSOME RESOURCES LIMITED